...
首页> 外文期刊>Frontiers in Medicine >Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
【24h】

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy

机译:监管科学至2025年:对欧洲药品局战略的利益相关者回应分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The pace of innovation is accelerating, and so medicines regulators need to actively innovate regulatory science to protect human and animal health. This requires consideration and consultation across all stakeholder groups. To this end, the European Medicines Agency worked with stakeholders to draft its Regulatory Science Strategy to 2025 and launched it for public consultation. The responses to this consultation were analyzed qualitatively, using framework analysis and quantitatively, to derive stakeholders' aggregate scores for the proposed recommendations. This paper provides a comprehensive resource of stakeholder positions on key regulatory science topics of the coming 5 years. These stakeholder positions have implications for the development and regulatory approval of both human and veterinary medicines.
机译:创新的步伐正在加速,因此药品监管机构需要积极创新监管科学,以保护人类和动物健康。 这需要跨所有利益相关者群体审议和协商。 为此,欧洲药物局与利益攸关方合作,将其监管科学战略起草到2025年,并推出了公众咨询。 定性地分析了对本次磋商的答复,使用框架分析和定量地进行了定量,以获得拟议建议的利益相关者的总成绩。 本文为未来5年的重点监管科学主题提供了综合利益攸关方职务的综合资源。 这些利益攸关方的职位对人类和兽医药物的发展和监管批准有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号